King-Friend Biochemical Pharmaceutical Co. Ltd.
King-Friend Biochemical Pharmaceutical Co. Ltd., commonly referred to as King-Friend, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and production of high-quality biochemical products, primarily focusing on APIs (Active Pharmaceutical Ingredients) and intermediates. With a strong operational presence across various regions, King-Friend has built a reputation for its innovative solutions in the pharmaceutical sector. The company’s core offerings include a diverse range of pharmaceutical raw materials, which are distinguished by their purity and compliance with international standards. Recognised for its commitment to quality and sustainability, King-Friend has achieved notable milestones, positioning itself as a trusted partner in the global pharmaceutical supply chain. Its dedication to research and development continues to drive its success in an increasingly competitive market.
DitchCarbon Score
How does King-Friend Biochemical Pharmaceutical Co. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
King-Friend Biochemical Pharmaceutical Co. Ltd.'s score of 16 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
King-Friend Biochemical Pharmaceutical Co. Ltd.'s reported carbon emissions
In 2023, King-Friend Biochemical Pharmaceutical Co. Ltd. reported total carbon emissions of approximately 1,628,340 kg CO2e. This figure includes Scope 1 emissions of about 20,290 kg CO2e, Scope 2 emissions of approximately 1,596,280 kg CO2e, and Scope 3 emissions of around 11,770 kg CO2e. Comparatively, in 2022, the company had total emissions of about 1,739,490 kg CO2e, with Scope 1 emissions at approximately 76,660 kg CO2e, Scope 2 emissions at around 1,648,730 kg CO2e, and Scope 3 emissions of about 14,100 kg CO2e. This indicates a reduction in total emissions of approximately 111,150 kg CO2e from 2022 to 2023. Despite these reductions, King-Friend Biochemical Pharmaceutical Co. Ltd. has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to operate within the global context of increasing regulatory and societal pressures to reduce greenhouse gas emissions, aligning with broader industry trends towards sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 76,660 | 00,000 |
| Scope 2 | 1,648,730 | 0,000,000 |
| Scope 3 | 14,100 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
King-Friend Biochemical Pharmaceutical Co. Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
